Clinical Trials Browser

Interventional × Myeloproliferative Disorders × pomalidomide × Clear all

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Phase 2 Active not recruiting

50 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT00669578 2019-12-30

CC-4047 in Treating Patients With Myelofibrosis

Phase 1/2 Completed

77 enrolled 9 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00949364 2017-09-25

Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage

Phase 2 Completed

Myeloproliferative Disorders